Back to Trades
Buy4
Kailera Therapeutics, Inc.
KLRA
Total Value
$25.6M
Net $25.0M bought
Purchases
$25.0M
1 transaction
Company Information
- Company Name
- Kailera Therapeutics, Inc.
- Ticker Symbol
- KLRA
- CIK
- 0002096997
Insider Information
- Name
- Koppel Adam
- Role
- Insider
- Location
- BOSTON, MA
Filing Details
- Filing Date
- Apr 20, 2026
- Transaction Date
- Apr 16, 2026
- Accession Number
- 0001193125-26-164407
- Form Type
- 4
- Net Trading Amount
- $25.0M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Apr 20, 2026 | Common Stock | 16,875,000 | — | C | — |
| Apr 20, 2026 | Common Stock | 4,145,768 | — | C | — |
| Apr 20, 2026 | Common Stock | 1,562,500 | $16.00 | Purchase | $25.0M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Apr 20, 2026 | Derivative | 16,875,000 | — | C | — |
| Apr 20, 2026 | Derivative | 4,145,768 | — | C | — |
| Apr 16, 2026 | Derivative | 38,300 | $16.00 | Grant/Award | $612.8K |
Footnotes
- (F1)Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
- (F2)Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
- (F3)The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to Dr. Koppel's continued service through each such vesting date.
- (F4)Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments").
- (F5)Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC ("BCLSI"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.